Is Daratumumab reimbursed by health insurance?

Daratumumab is a revolutionary drug widely used to treat multiple myeloma (Multiple Myeloma), a malignant bone marrow cancer that mainly affects the immune system and bone marrow. Daratumumab has achieved remarkable therapeutic results by specifically interfering with tumor growth and immune system regulation.

Daratumumab has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The price is about more than 5,000. Medical insurance reimbursement must meet the reimbursement conditions. For specific prices and medical insurance policies, please consult the local hospital pharmacy or medical insurance bureau. Currently, there is only the original drug of daratumumab in foreign countries. The cheaper one is the Turkish original drug, which costs around 5,000. The ingredients and efficacy are consistent with the domestic original drug.

The drug belongs to a class of monoclonal antibody drugs that specifically target theCD38 receptor that is overexpressed in multiple myeloma. CD38The receptor is a protein located on the surface of plasma cells, prompting the growth of these malignant cells and weakening the function of the immune system. Daratumumab inhibits tumor growth by binding to the CD38 receptor, triggering the immune system to attack and destroy cancer cells.

This innovative drug is a significant breakthrough in not only improving patient survival rates, but also improving quality of life and reducing pain and other symptoms associated with multiple myeloma. It offers new hope to patients who previously had limited treatment options.

While daratumumab has been successful in the treatment of multiple myeloma, it is also being explored in further studies for its potential in other blood cancer types, such as lymphoma and chronic lymphocytic leukemia. This reflects the promise and importance of targeted therapy in the field of cancer treatment.